Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Be between 5 and 35 years of age, inclusive.~2. Have severe SCD or transfusion dependent beta-thalassemia major, regardless of the genotype with the diagnosis confirmed by Hb studies. Transfusion dependence is defined as requiring at least 100 mL/kg/year of packed red blood cells (pRBCs).~3. Be eligible for allogeneic hematopoietic stem cell transplant (HSCT) based on institutional medical guidelines, but without a matched related donor.~4. Be willing and able, in the Investigator's opinion, to comply with the study procedures outlined in the study protocol.~5. Have been treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.~   Participants with severe SCD also must:~6. Have failed to achieve adequate clinical benefit following hydroxyurea treatment with sufficient dosage, for at least 4 months unless this treatment was not indicated or not well tolerated.~7. Have 1 or more of the following poor prognostic risk factors:~   * Recurrent vaso occlusive crises (at least 2 episodes in the preceding year or in the year prior to start of a regular transfusion program).~  * Presence of any significant cerebral abnormality on magnetic resonance imaging (MRI) (such as stenosis or occlusions).~  * Stroke without any severe cognitive disability.~  * Osteonecrosis of 2 or more joints.~  * Anti-erythrocyte alloimmunization (\>2 antibodies).~  * Presence of sickle cell cardiomyopathy documented by Doppler echocardiography.~  * Acute chest syndrome (at least 2 episodes) defined by an acute event with pneumonia-like symptoms (e.g., cough, fever \[\>38.5°C\], acute dyspnea, expectoration, chest pain, findings upon lung auscultation, tachypnea, or wheezing) and the presence of a new pulmonary infiltrate. Participants with a chronic oxygen saturation \<90% (excluding periods of SCD crisis) or carbon monoxide diffusing capacity (DLco) less than 60% in the absence of an infection should not be included in the study.~8. Participants with severe SCD and cerebral vasculopathy (defined by overt stroke; abnormal transcranial Doppler \[\> 170 cm/sec\]; or occlusion or stenosis in the polygon of Willis; or presence of Moyamoya disease) may be enrolled only with approval by the Comite de Surveillance after review of safety and efficacy data from \>or= 2 SCD participants without cerebral vasculopathy treated with LentiGlobin BB305 Drug Product~Exclusion Criteria:~1. Availability of a willing 10 /10 matched human leukocyte antigen (HLA) identical sibling hematopoietic cell donor, unless recommendation for enrollment is provided by the Comite de Surveillance following a review of the case.~2. Clinically significant, active bacterial, viral, fungal, or parasitic infection.~3. Contraindication to anesthesia for bone marrow harvesting.~4. Any prior or current malignancy, myeloproliferative or immunodeficiency disorder.~5. A white blood cell (WBC) count \<3×10\^9/L and/or platelet count \<120×10\^9/L.~6. History of major organ damage including:~   * Liver disease, with transaminase levels \>3× upper limit of normal.~  * This observation will not be exclusionary if a liver biopsy shows no evidence of extensive bridging fibrosis, cirrhosis, or acute hepatitis.~  * Histopathological evidence of extensive bridging fibrosis, cirrhosis, or acute hepatitis on liver biopsy.~  * Heart disease, with a left ventricular ejection fraction \<25%.~  * Kidney disease with a calculated creatinine clearance \<30% normal value.~  * Severe iron overload, which in the opinion of the physician is grounds for exclusion.~  * A cardiac T2\* \<10 ms by magnetic resonance imaging (MRI).~  * Evidence of clinically significant pulmonary hypertension requiring medical intervention.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- LentiGlobin BB305 Drug Product (Type: EXPERIMENTAL): Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).